Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks

Investigational New Drugs

Volumn 21, Issue 1, 2003, Pages 85-97

  Davis, Alison J ^e   Gelmon, Karen A ^a   Siu, Lillian L ^d   Moore, Malcolm J ^e   Britten, Carolyn D ^a   Mistry, Nisha ^e   Klamut, Henry ^e   D'Aloisio, Susan ^a   MacLean, Martha ^e   Wainman, Nancy ^b   Ayers, Debbie ^a   Firby, Patricia ^e   Besterman, Jeffrey M ^c   Reid, Gregory K ^c   Eisenhauer, Elizabeth A ^e  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b Institut national du cancer du Canada   (Canada)

^c METHYLGENE INC   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e NONE

Author keywords

Antisense; DNS; Methyltransferase; Phase I trial

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DNA METHYLTRANSFERASE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HEMOGLOBIN F; MG 98; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; FATIGUE; FEMALE; FEVER; HUMAN; IC 50; MALE; NAUSEA; PRIORITY JOURNAL; STEADY STATE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FETAL HEMOGLOBIN; HUMANS; INFUSIONS, INTRAVENOUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PROTEINS; RNA, MESSENGER; THIONUCLEOTIDES; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; VIMENTIN;

EID: 12444297637     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022976528441     Document Type: Conference Paper

References (37)

1. Bestor TH, Laudano A, Mattaliano R, Ingram V: Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J Mol Biol 203: 971-983, 1988
2. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 21: 163-167, 1999
3. Eng C, Herman JG, Baylin, SB: A bird's eye view of global methylation. Nat Genet 24: 101-102, 2000
4. Adams RL, McKay EL, Craig LM, Burdon RH: Mouse DNA methylase: methylation of native DNA. Biochem Biophys Acta 561: 345-357, 1979
5. Razin A, Szyf M: DNA methylation patterns. Formation and function. Biochem Biophys Acta 782: 331-342, 1984
6. Yoder JA, Soman NS, Verdine GL, Bestor TH: DNA (cytosine-5)-methyltransferases in mouse cells and tissues. J Mol Biol 270: 385-395, 1997
7. Yisraeli J, Szyf M: The pattern of methylation of eukaryotic genes. In: Razin A, Cedar H, Riggs AD (eds) DNA Methylation: Biochemistry and Biological Significance. 1984, pp 353-378
8. Laird P: Oncogenic mechanisms mediated by DNA methylation. Mol Med Today 3: 223-229, 1997
9. Jones PA: The DNA methylation paradox. Trends Genet 15: 34-37, 1999
10. Szyf M: DNA methylation properties: consequences for pharmacology. Trends Pharmacol Sci 15: 233-238, 1994
11. Nan X, Campoy FJ, Bird A: MeCP2 is a transcription repressor with abundant binding sites in genomic chromatin. Cell 88: 471-481, 1997
12. Szyf M: The DNA methylation machinery as a target for anticancer therapy. Pharmacol Ther 70: 1-37, 1996
13. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H-J, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C: Aberrant CpG-island methylation has non-random and tumor-type specific patterns. Nat Genet 25: 132-138, 2000
14. Strathdee G, MacKean MJ, Illand M, Brown R: A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18: 2335-2341, 1999
15. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354, 2000
16. Orr RM, Monia BP: Antisense therapy for cancer. Curr Res Mol Ther 1: 102-108, 1998
17. Shaw JP, Kent K, Bird J, Fishback J, Froehler, B: Modified deoxyoligonucleotides stable to exonucleases degradation in serum. Nucleic Acids Res 19: 747-750, 1991
18. Inoue H, Hayase Y, Imura A, Iwai S, Miura K, Ohtsuka, E: Synthesis and hybridization studies on two complementary nona (2′-O-methyl) ribonucleotides. Nucleic Acid Res 15: 6131-6148, 1987
19. Zhang R, Iyer RP, Yu D, Tan W, Zhang X, Lu Z, Zhao H, Agrawal, S: Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration. J Pharmacol Exp Ther 278: 971-979, 1996
20. Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang, R: Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci USA 94: 2620-2625, 1997
21. Beaulieu N, Fournel M, MacLeod AR: Antitumor activity of MG98, an antisense oligodeoynucleotide targeting DNA Methyltransferase-1 (DNMT1). Proc AACR-NCI-EORTC 728: 28,148, 2001
22. DeSimone J, Heller P, Hall L, Zwiers, D: 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci USA 79: 4428-4431, 1982
23. Ley TJ, Anagnou NP, Noguchi CT, Schechter AN, DeSimone J, Heller P, Nienhuis AW: DNA methylation and globin gene expression in patients treated with 5-azacytidine. Prog Clin Biol Res 134: 457-474, 1983
24. Ley TJ, DeSimone J, Noguchi CT, Turner PH, Schechter AN, Heller P, Nienhuis AW: 5-Azacytidine increases gammaglobin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 62: 370-380. 1983
25. Carr BI, Rahbar S, Doroshow JH, Blayney D, Goldberg D, Leong L, Asmeron, Y: Fetal hemoglobin gene activation in a phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma. Cancer Res 47: 4199-4201, 1987
26. Bourque AJ, Cohen, AS: Quantitative analysis of phosphorothioate oligonucleotides in biological fluids using direct injection fast anion-exchange chromatography and capillary gel electrophoresis. J Chromatogr B Biomed Appl 662: 343-349, 1994
27. Betke K, Marti HR, Schlicht I: Estimation of small percentages of foetal haemoglobin. Nature 194: 1877-1878, 1959
28. Ho PTC, Parkinson DR: Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol 24: 187-202, 1997
29. Benimetskaya L, Tonkinson J, Stein CA: Determination of cellular internalization of fluoresceinated oligonucleotides. Meth Enzymol 313: 287-297, 2000
30. Henry SP, Bolte A, Auletta C, Kornbrust DJ: Evaluation of the toxicity of ISIS 2302, a phosphorothioate Oligonucleotide, in a four-week study in Cynomolgus monkeys. Toxicology 120: 145-155, 1997
31. Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Sikic BI: Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res 5: 3357-3363, 1999
32. Cunningham CC, Holmlund JT, Schiller JH, Geary RS, Kwoh TJ, Dorr A, Nemunaitis J: A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 6: 1626-1631, 2000
33. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, diStefano F, Cotter FE: Phase I clinical and pharmacokinetic study of bcl-2 antisense Oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18: 1812-1823, 2000
34. Stewart D, Donehower R, Eisenhauer E, Wainman N, Moore M, Bonfils C, Reid G: A phase I and pharmacokinetic (PK) study of MG98, a human DNA methyltransferase (MeTase) antisense oligonucleotide, given as a 2-hour twice weely (BIW) infusion 3 out of every 4 weeks. Proceedings of the 11th NCI/EORTC/AACR Symposium, 148 (abstract no. 528), 2000
35. O'Dwyer PJ, Stevenson JP, Gallagher M, Cassella A, Vasilevskaya I, Monia BP, Holmlund J, Dorr FA, Yao KS: c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res 5: 3977-3982, 1999
36. Geary RS, Leeds JM, Henry SP, Monteith DK, Levin A: A. Antisense oligonucleotide inhibitors for the treatment of cancer: I. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 12: 383-393, 1997
37. Pfeifer GP: p53 mutational spectra and the role of methylated CpG sequences. Mutat Res 450: 155-166, 2000